[Oral toxicity of targeted anticancer therapies]

V Sibaud; F Boralevi; E Vigarios; J-C Fricain

doi:10.1016/j.annder.2014.03.009

[Oral toxicity of targeted anticancer therapies]

Ann Dermatol Venereol. 2014 May;141(5):354-63. doi: 10.1016/j.annder.2014.03.009. Epub 2014 Apr 13.

[Article in French]

Authors

V Sibaud¹, F Boralevi², E Vigarios³, J-C Fricain⁴

Affiliations

¹ Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France. Electronic address: [email protected].
² Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, unité de dermatologie pédiatrique, hôpital Pellegrin enfants, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
³ Odontologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France.
⁴ Unité de médecine bucco-dentaire, consultation pluridisciplinaire de pathologie de la muqueuse buccale, UFR odontologie Bordeaux, 16-20, cours de la Marne, 33076 Bordeaux cedex, France; Pôle odontologie et santé buccale, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

PMID: 24835648
DOI: 10.1016/j.annder.2014.03.009

Abstract

While toxicity of targeted anticancer therapies on the oral mucosa seems relatively frequent in clinical practice, it has not been properly characterized to date, apart from aphthous-like lesions due to mTOR inhibitors. Herein, we report the main oral lesions associated with these new therapies, with a description of the most frequent but also the most characteristic clinical manifestations of these drugs, such as anti-EGFR-induced mucositis, BRAF-inhibitor-associated hyperkeratosis, benign migratory glossitis and osteonecrosis of the jaw observed with angiogenesis inhibitors, as well as lesions more specifically linked with imatinib.

Keywords: Aphthous-like lesions; Benign migratory glossitis; Glossite migratrice bénigne; Hyperkeratosis; Hyperkératose; Lésions buccales; Mucite; Mucositis; Oral lesions; Osteonecrosis of the jaw; Ostéonécrose de la mâchoire; Targeted therapies; Thérapies ciblées; Ulcérations aphtoïdes.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / adverse effects
Benzamides / adverse effects
ErbB Receptors / antagonists & inhibitors
Glossitis, Benign Migratory / chemically induced
Humans
Hyperpigmentation / chemically induced
Imatinib Mesylate
Indoles / adverse effects
Maxillary Diseases / chemically induced
Maxillary Diseases / pathology
Molecular Targeted Therapy / adverse effects*
Molecular Targeted Therapy / methods
Mouth Mucosa / drug effects
Mouth Mucosa / pathology
Osteonecrosis / chemically induced
Osteonecrosis / pathology
Piperazines / adverse effects
Protein Kinase Inhibitors / adverse effects
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Pyrimidines / adverse effects
Pyrroles / adverse effects
Radiation Injuries / complications
Radiotherapy / adverse effects
Stomatitis / chemically induced*
Stomatitis / pathology
Stomatitis, Aphthous / chemically induced
Stomatitis, Aphthous / pathology
Sunitinib
TOR Serine-Threonine Kinases / adverse effects

Substances

Angiogenesis Inhibitors
Benzamides
Indoles
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
Imatinib Mesylate
ErbB Receptors
BRAF protein, human
Proto-Oncogene Proteins B-raf
TOR Serine-Threonine Kinases
Sunitinib